Astrana HealthASTH +0.28%87 EV-to-EBIT is 24.87 as of Jul. 07, 2026, which is 61% above its 10-year median of 15.49. GuruFocus rates ASTH with a GF Score™ of 87/100 and a GF Value™ of $82.79 (Significantly Undervalued). The stock has 8 warning signs investors should review. Among 469 Healthcare Providers & Services companies, Astrana Health ranks worse than 68.87% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Astrana Health's Enterprise Value for the quarter that ended in Mar. 2026 was $1,564 Mil.
Astrana Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $108 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astrana Health EV-to-EBIT Related Terms
Astrana Health EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Astrana Health's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Astrana Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astrana Health EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Astrana Health's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Astrana Health's EV-to-EBIT falls into.
Astrana Health's current Enterprise Value is $2,696 Mil.
Astrana Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $108 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astrana Health (ASTH) has a EV-to-EBIT of 24.87 as of Jul. 07, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Astrana Health and its competitors. This is 61% above median its historical median of 15.49. According to the industry distribution chart, Astrana Health ranks #323 out of 469 companies in the Healthcare Providers & Services industry, placing it in the top 68.9%.
Is Astrana Health's EV-to-EBIT too high?
Astrana Health's current EV-to-EBIT of 24.87 is 61% above median its 10-year median of 15.49. The Healthcare Providers & Services industry median EV-to-EBIT is 15.77. Astrana Health's value of 24.87 is 57.7% above this industry median. Based on the distribution chart, Astrana Health ranks #323 out of 469 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Astrana Health has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Astrana Health's EV-to-EBIT compare to SGRY and SEM?
According to the Healthcare Providers & Services industry distribution chart, Astrana Health ranks #323 out of 469 companies for EV-to-EBIT. This places Astrana Health in the lower half of its industry. The industry median EV-to-EBIT is 15.77. Astrana Health's value of 24.87 is 57.7% above this benchmark. While the company's 10-year median is 15.49 vs. the industry median of 15.77, Astrana Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.77, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astrana Health's current EV-to-EBIT of 24.87 is 57.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Astrana Health and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astrana Health's current EV-to-EBIT is 24.87, which is 61% above median its own 10-year median of 15.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astrana Health stock overvalued right now?
Based on GuruFocus' analysis, Astrana Health (ASTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $82.79, compared to a current price of $47.04 — trading 43.2% below its estimated fair value. The current EV-to-EBIT is 24.87, which is 61% above median its 10-year median of 15.49 and 57.7% above the Healthcare Providers & Services industry median of 15.77. Astrana Health's overall GF Score™ is 87/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Astrana Health (ASTH), the current EV-to-EBIT is 24.87 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astrana Health (ASTH) Overvalued in 2026?
Based on GuruFocus' analysis, Astrana Health stock appears to be undervalued.
The current stock price of $47.04 is trading 43.2% below its estimated GF Value™ of $82.79.
GuruFocus considers Astrana Health to be Significantly Undervalued.
Key valuation signals for ASTH:
EV-to-EBIT: 24.87 (61% above median its 10-year median of 15.49)
GF Value™: $82.79 vs. price of $47.04 (43.2% below fair value)
Industry Position: 57.7% above the Healthcare Providers & Services median (#323 of 469)
No single metric tells the full story. See the ASTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
87GF Score
Get the complete analysis for ASTH
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASTH has been successfully added to your 
